Humanigen, Inc. (NASDAQ:HGEN) Insider Buys $340,452.00 in Stock

Humanigen, Inc. (NASDAQ:HGENGet Rating) insider Dale Chappell purchased 173,700 shares of the firm’s stock in a transaction that occurred on Wednesday, May 18th. The shares were acquired at an average cost of $1.96 per share, with a total value of $340,452.00. Following the completion of the transaction, the insider now directly owns 8,066,575 shares of the company’s stock, valued at approximately $15,810,487. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

Dale Chappell also recently made the following trade(s):

  • On Friday, May 20th, Dale Chappell acquired 545,488 shares of Humanigen stock. The stock was acquired at an average cost of $2.23 per share, for a total transaction of $1,216,438.24.
  • On Friday, March 11th, Dale Chappell bought 1,000,000 shares of Humanigen stock. The shares were acquired at an average cost of $3.00 per share, with a total value of $3,000,000.00.

Shares of HGEN traded up $0.02 during mid-day trading on Friday, hitting $2.26. The stock had a trading volume of 1,712,400 shares, compared to its average volume of 1,447,417. Humanigen, Inc. has a 52 week low of $1.67 and a 52 week high of $23.53. The business has a fifty day moving average price of $2.59 and a 200-day moving average price of $3.44. The firm has a market cap of $159.63 million, a P/E ratio of -0.71 and a beta of -1.01.

Humanigen (NASDAQ:HGENGet Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.17. The business had revenue of $1.04 million for the quarter, compared to analysts’ expectations of $1.04 million. Humanigen had a negative return on equity of 24,421.51% and a negative net margin of 4,640.77%. As a group, research analysts predict that Humanigen, Inc. will post -0.69 earnings per share for the current year.

Separately, Zacks Investment Research lowered shares of Humanigen from a “hold” rating to a “sell” rating in a research report on Wednesday, May 4th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $21.00.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Morgan Stanley lifted its position in shares of Humanigen by 1,884.6% during the second quarter. Morgan Stanley now owns 128,841 shares of the company’s stock worth $2,239,000 after acquiring an additional 122,349 shares in the last quarter. Royal Bank of Canada boosted its position in shares of Humanigen by 44.2% during the 2nd quarter. Royal Bank of Canada now owns 9,950 shares of the company’s stock valued at $172,000 after acquiring an additional 3,050 shares during the last quarter. Invesco Ltd. purchased a new position in Humanigen in the 2nd quarter worth approximately $260,000. Wells Fargo & Company MN grew its position in Humanigen by 22.4% in the second quarter. Wells Fargo & Company MN now owns 3,675 shares of the company’s stock worth $64,000 after acquiring an additional 673 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in Humanigen in the third quarter valued at $108,000. 64.34% of the stock is currently owned by institutional investors.

Humanigen Company Profile (Get Rating)

Humanigen, Inc, a clinical stage biopharmaceutical company, develops a portfolio of anti-inflammatory immunology and immuno-oncology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which has completed Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that is in Phase II clinical trial in patients with chronic myelomonocytic leukemia.

Read More

Insider Buying and Selling by Quarter for Humanigen (NASDAQ:HGEN)

Receive News & Ratings for Humanigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humanigen and related companies with MarketBeat.com's FREE daily email newsletter.